Compare CMPX & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPX | EMBC |
|---|---|---|
| Founded | 2014 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.4M | 719.7M |
| IPO Year | N/A | N/A |
| Metric | CMPX | EMBC |
|---|---|---|
| Price | $5.14 | $11.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $13.44 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 2.0M | 641.7K |
| Earning Date | 11-05-2025 | 11-25-2025 |
| Dividend Yield | N/A | ★ 5.39% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.62 |
| Revenue | N/A | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | N/A | $0.09 |
| P/E Ratio | ★ N/A | $6.87 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $9.20 |
| 52 Week High | $5.86 | $21.23 |
| Indicator | CMPX | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 26.27 |
| Support Level | $5.13 | $12.10 |
| Resistance Level | $5.76 | $12.56 |
| Average True Range (ATR) | 0.34 | 0.75 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 34.96 | 0.40 |
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.